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Antiphospholipid syndrome (APS) is amultiorgan disease often affecting the central nervous system (CNS). Typically, neurological
manifestations of APS include thrombosis of cerebral vessels leading to stroke and requiring prompt initiation of treatment with
antiplatelet drugs or anticoagulant therapy. In these cases, alterations of the coagulation system at various levels caused by multiple
effects of antiphospholipid antibodies (aPL) have been postulated to explain the vascular damage to the CNS in APS. However,
several nonvascular neurological manifestations of APS have progressively emerged over the past years. Nonthrombotic, immune-
mediated mechanisms altering physiological basal ganglia function have been recently suggested to play a central role in the
pathogenesis of these manifestations that include, among others, movement disorders such as chorea and behavioral and cognitive
alterations. Similar clinical manifestations have been described in other autoimmune CNS diseases such as anti-NMDAR and anti-
VGCK encephalitis, suggesting that the spectrum of immune-mediated basal ganglia disorders is expanding, possibly sharing some
pathophysiologicalmechanisms. In this review, wewill focus on thrombotic and nonthrombotic neurologicalmanifestations of APS
with particular attention to immune-mediated actions of aPL on the vascular system and the basal ganglia.
1. Introduction
Clinical manifestations of antiphospholipid syndrome (APS)
encompass a wide variety of symptoms that can involve mul-
tiple organs at different times over the course of the disease,
including the central nervous system (CNS). According to
the current clinical diagnostic criteria for APS [1], one or
more episodes of arterial, venous, or small vessel thrombosis
in any tissue or organ must be demonstrated by means of
appropriate imaging studies or histopathology or pregnancy
morbidity must be present in the patient’s clinical history.
Neurological disturbances due to vascular damage of the
CNS are well known in APS and stroke can be the presenting
feature of the disease; however, in several patients showing
neurological symptoms, no evidence of vascular injury can
be detected in the CNS even after extensive imaging inves-
tigations. In these patients, mechanisms other than vascular
damage have been postulated to play a pathogenetic role in
the development of neurological manifestations. At present,
however, the only neurologicalmanifestation that satisfies the
diagnostic criteria for APS remains cerebral ischemia.
Clinicians should be aware of the constellation of neuro-
logical symptoms associated with APS, in order to avoid any
diagnostic delay and promptly start an appropriate treatment.
In this paper, we will review the main molecular mecha-
nisms underlying the pathogenesis of vascular and nonvascu-
lar damage leading to cerebral dysfunction and neurological
manifestations in APS.
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2. Neurological Manifestations in APS
In 1983, in the original description of the syndrome, Hughes
pointed out the importance of cerebral involvement in
patients with APS, including cerebrovascular accidents and
myelitis [2].
Since then, a number of neurological manifestations have
been repeatedly reported in association with primary and
secondary APS, sometimes in the absence of stroke, raising
the hypothesis that aPL may exert a direct pathogenetic
role in the CNS by mechanisms that go beyond vascular
thrombosis.
Stroke and transient ischemic attacks (TIA) are the most
common manifestation of APS that is an important cause
of juvenile stroke, with an age at presentation that is a
decade younger than the typical population with classical
cardiovascular risk factors [3]. The presence of antiphospho-
lipid antibodies (aPL) in a cohort of 356 unselected patients
from a neurological clinic was found to be 15%, with 45%
of aPL-positive patients presenting stroke and 13% of cases
presenting TIA [4]. In this cohort, the medial cerebral artery
was the site most commonly affected by thrombosis, but any
brain region can be interested by vascular thrombosis in APS
[5, 6]. A recent comprehensive review of the available data
from the literature [7] estimated a prevalence of 13.5% of aPL
in patients with stroke/TIA, although it is difficult to establish
with sufficient confidence the true prevalence of aPL in these
patients and in the general population because of different
methods used to detect aPL in previously published studies.
Recurrent stroke in patients with aPL has been reported,
with no differences between primary and secondary APS [8]
and evidence of shortest time to subsequent ischemic event in
patientswith highest titers of anticardiolipin (aCL) antibodies
[3]. Data on the relationship between the recurrence rate
of stroke and the levels of aCL antibodies, however, are
controversial, with some studies failing to clearly demonstrate
this association (see [9] for review).
Cerebral venous thrombosis (CVT) is not a common
manifestation of APS, because of a more selective vulner-
ability of the arterial system to thrombotic events. CVT
occurs at young age with more extensive superficial and deep
cerebral venous system involvement in aPL-positive patients
as compared to negative ones [10]. aPL has been suggested to
act as a risk factor for CVT in association with concomitant
additional risk factors that predispose to thromboembolism,
such as protein C resistance and Leiden’s factor V [11].
Recurrent stroke in APS can lead to multifocal damage to
the CNS and cause multi-infarct dementia, reported for the
first time in 1987 [12].
However, in a case-control study, dementia similar to
Alzheimer’s disease has been described in 6% of elderly
subjects, who were found to have elevated aCL IgG titers
without features of autoimmune disease [13]. Subtle cognitive
dysfunction such as attention and memory deficit and dif-
ficulty in concentration has also been described in patients
with aPL without ischemic lesions of the brain (see [9] for
review). Cognitive dysfunction has been mainly reported
in patients with systemic lupus erythematosus (SLE) and
APS and persistently elevated IgG and IgA aCL levels were
associated with reduced psychomotor speed and executive
dysfunctions [14].
Movement disorders are known to be part of the clinical
spectrum of APS.
Chorea is a hyperkinetic movement disorder charac-
terized by involuntary, patternless, purposeless movement
continuously flowing from a body part to another in an
unpredictable way.
Several studies have established a relationship between
chorea and aPL, especially in APS secondary to SLE, in which
chorea has been described in 58% of cases in a previously
published series by Cervera et al. [15], and the prevalence of
aPL in patients with lupus chorea has been reported in up to
92% of patients [15–17]. Chorea is also the most commonly
encountered movement disorder in primary APS, with an
estimated frequency of 1.3% [18]. Since vascular lesions in
the basal ganglia are present only in a subset of patients with
chorea, a direct binding of aPL to CNS antigens has been
postulated [19].
Other less frequent movement disorders previously
described in APS include tics [20, 21], corticobasal syndrome
[21, 22], hemidystonia [23, 24], paroxysmal nonkinesigenic
dyskinesias [25], parkinsonism [26], cerebellar ataxia [27],
and complex mixed presentations [28]. For a more compre-
hensive review on movement disorders in SLE and primary
APS, see Baizabal-Carvallo [29].
Nonthrombotic neurological manifestations occur in up
to 40% of patients with elevated aPL [4] and include
seizures, headache, transversemyelitis, sensorineural hearing
loss, multiple sclerosis, and peripheral neuropathy including
Guillain-Barre` syndrome [30].
Seizures in APS are present in about 10% of patients
[31] and either can be secondary to vascular lesions or
occur without evidence of previous stroke. In this regard, a
functional interaction between aPL andneuronalmembranes
has been demonstrated in vitro by inducing depolarization
of synaptoneurosomes by means of IgG from APS patients.
This has been suggested to cause epilepsy in APS, and
an association between serum levels of aPL and seizure
occurrence has been described [32]. On the other hand,
stroke and cerebrovascular disease have been indicated in
different studies as an independent risk factor for developing
seizures in APS [31, 33].
Transverse myelitis (TM) is a rare manifestation of APS
with an estimated prevalence of <1%; it is characterized by
acute inflammation affecting mainly the thoracic segment
of the spinal cord that causes sensory loss below the level
of the lesion, motor, and sphincter disturbances [34]. Spinal
cord MRI generally shows lesions exceeding three vertebral
segments in length with central involvement, but shorter
lesions can be detected [35]. In SLE, a strong association
between aPL positivity and TM has been reported [36];
however, the pathophysiology of TM is still controversial;
vascular injury secondary to vasculitis, hypercoagulable state,
and a direct role of antineuronal antibodies have all been
postulated [34].
With regard to the peripheral nervous system, its involve-
ment inAPS can be present either in the formofmononeuritis
multiplex (often caused by vasculitis associated with SLE
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Table 1: Neurological manifestations of APS.
Neurological manifestations associated with
antiphospholipid syndrome Features
Thrombotic manifestations
Spinal cord stroke Uncommon feature; less frequent than transverse myelitis
Acute ischemic encephalopathy Uncommon feature in APS secondary to SLE; presents with tetraparesis, confusion,and hyperreflexia
Ischemic stroke
Transient ischemic attack (TIA)
The most common manifestations of APS; important cause of juvenile stroke; any
brain region can be interested
Cerebral venous thrombosis Uncommon vascular manifestation
Nonthrombotic manifestations
Headache Frequent and often untreatable; no definite association between aPL positivity andtype of headache [34]
Multiple sclerosis APS can mimic multiple sclerosis; no definite tests to differentiate these entities areavailable
Transverse myelitis Rare acute inflammatory manifestation; more common in APS secondary to SLE
Sensorineural hearing loss Acute onset in the presence of aPL may be a manifestation of APS [37]
Guillain-Barre` syndrome Antiphospholipid antibodies probably produced as a result of myelin damage
Peripheral neuropathy Mononeuritis multiplex due to vasculitis is most commonly found in SLE; axonalneuropathy can be asymptomatic in PAPS
Cognitive dysfunction and dementia Caused by multiple brain strokes; Alzheimer’s disease-like dementia in 6% of cases
Idiopathic intracranial hypertension Can be the presenting feature of APS
Epilepsy In 10% of patients; primary or secondary to stroke
Chorea and other movement disorders Rarely due to stroke in the basal ganglia; frequent in patients with APS secondary toSLE
andother immunorheumatological diseases) or as peripheral,
mainly axonal, neuropathy that is often asymptomatic and
revealed only by means of electrophysiological studies [34].
Thrombotic and nonthrombotic neurological manifesta-
tions in APS are listed in Table 1.
3. Thrombosis in APS:
Pathogenetic Mechanisms
Many studies have shown that aPL are pathogenetic in
APS and play a prothrombotic role both in the arterial
and in the venous vascular system [38, 39]. At present, the
most likely hypothesis to explain this phenomenon is that
these antibodies exert multiple actions at different levels
ultimately leading to alteration of the coagulation system in a
prothrombotic manner.
The predominant antibodies in APS are directed against
protein antigens that bind to anionic phospholipids, such as
Beta 2-glycoprotein I (B2GPI) and prothrombin. Prothrom-
bin is a proenzyme cleaved by the prothrombinase complex
and subsequently leads to the generation of thrombin. B2GPI
is a plasma protein consisting of four domains (from I
to IV) of approximately 60 amino acids and one domain
(domain V) of 84 amino acids, through which binding to
anionic phospholipids takes place [40]. Antibodies against
B2GPI seem to display different domain specificity; in par-
ticular, antibodies recognizing domain I, described as highly
immunogenic, represent most of the anti-B2GPI antibodies
and have been detected in many patients with a history
of thrombosis, whereas antibodies directed against domain
V do not seem to be associated with thrombosis [41]. aPL
bind to an epitope present in domain I that is normally
not available to binding because of the physiological circular
conformation of B2GPI. Under specific conditions, such as
infections, the protein conformation can change resulting in
exposure of the immunogenic epitope of domain I, to which
autoantibodies bind [38].
Platelet factor 4 (PF4) binds to dimerized B2GPI, and
this complex is recognized by anti-B2GPI antibodies. The
PF4-B2GPI complex activates platelets by p38 MAP kinase
phosphorylation, GPIIb/3a receptor expression, and throm-
boxane B2 synthesis and release, thus leading to platelets
activation and thrombosis [42]. Othermechanisms of platelet
activation have been described, including the interaction
between B2GPI-recognizing antibodies and the glycoprotein
Ib- (GPIb-) apolipoprotein receptor E2 (APOER2) complex
and the binding of B2GPI/anti-B2GPI complexes through
LDL receptor-related proteins [43–46].
The hypercoagulable state promoted by aPL is thought
to be based on several other mechanisms. In fact, aPL
induce the overproduction of tissue factor (TF), thus acti-
vating the extrinsic pathway of the coagulation, increase
resistance to activated protein C (APC), and bind to annexin
A5 (AnxA5). This protein binds to the exposed negatively
charged phospholipids on the surface of the cell making them
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unavailable to other coagulation factors and thus exerting an
anticoagulant activity. Antiphospholipid antibodies disrup-
tion of annexin A5 anticoagulant shield is thought to be an
important thrombogenic mechanism [47].
Endothelial dysfunction is an additional importantmech-
anism underlying thrombotic events in APS. aPL can in fact
induce a procoagulant activity in endothelial cells (EC) by
inducing expression of procoagulant, proinflammatory, and
proadhesive molecules that favors the binding of circulating
leukocytes. After aPL binding, EC increase the expression
of adhesion molecules (ICAM-1, VCAM-1, and E-selectin)
[48], upregulate tissue factor transcription through p38MAP
kinase phosphorylation and the NF-𝜅B pathway [49, 50], and
increase cytokines/chemokines production (IL-4, IL-6, IL-8,
MCP-1, and TNF-𝛼) [51–54].
Finally, a possible pathogenetic role of the complement
system in APS-associated thrombosis has been suggested
in animal models of mice deficient for the complement
factors C3 and C5 that do not show thrombosis or pregnancy
loss induced by aPL [55, 56]. Moreover, elevated levels
of complement activation products have been detected in
plasma of patients with APS who had a cerebral ischemic
event as compared to APS patient without ischemia [57].
4. Nonthrombotic Manifestations in APS
Beside vascular lesions in the CNS and the underlying
thromboticmechanisms, a direct effect of aPL in the CNS has
been postulated to explain neurological symptoms without
evidence of cerebral stroke. Data from animal models largely
support this hypothesis.
Mice immunized with themain APS autoantigen, B2GPI,
show behavioral changes such as higher stair-climbing
activity and anxiety/exploratory behavior as compared to
adjuvant-immunizedmice in a staircase apparatus [58]; simi-
lar results have been obtained inmice by immunizationwith a
pathogenic monoclonal antibody [59]. In both experimental
APS models, no vascular damage to the CNS could be
detected.
Passive immunization of mice with B2GPI as well as
intraventricular injection of IgG aPL purified from patients’
serum leads to memory and learning deficits more evident
4-5 months after single immunization [60, 61] with evidence
of antibodies binding to specific areas of the brain, including
hippocampus, cortex, and choroid plexus.
More recently, Katzav et al. demonstrated that, in amouse
model of Alzheimer’s disease carrying the APP 695 SWE
mutation, immunization with B2GPI was associated with
mature amyloid plaques deposition on a female background
and the development of motor hypoactivity and impaired
cognition. The long-term exposure to elevated aPL levels
of susceptible brains would therefore seem to induce AD
pathology. The authors propose that APP, which also plays
a role as coagulation inhibitor, is affected in APS [62] and
that this leads to exposure of the brain to high levels of
thrombin, that in turn causes consumption of coagulation
inhibitors such as APP, and subsequent upregulation of APP
synthesis that may determine an increased risk of developing
Alzheimer’s pathology [63].
Another possible link between aPL and cognitive dys-
function would be the increased release of proinflammatory
cytokines. Indeed, it is well documented that, in neurode-
generative diseases characterized by cognitive dysfunction
and in particular in AD, proinflammatory cytokines play a
significant pathogenetic role [64, 65].
The pathogenesis of movement disorders, especially
chorea, in APS has recently been a matter of debate. The
first hypothesis to explain involuntary movements in APS
was the involvement of lenticulostriate arteries in thrombotic
processes producing ischemia of the basal ganglia. However,
basal ganglia lesions in APS-related chorea have been rarely
reported [15]. Despite the technical limitations of imaging
studies that might have overlooked small-vessel thrombosis
in the basal ganglia, alternative pathogenetic mechanisms
have been proposed to explain movement disorder in APS,
based on recent works that demonstrated a direct binding of
aPL to cells in the CNS.
How aPL and lymphocytes may gain access to the CNS
is still not completely understood. aPL may enter the CNS
by causing an alteration of the endothelial cells, as previ-
ously discussed, ultimately leading to endothelial dysfunction
[66, 67]. This may cause a disruption of the blood-brain
barrier (BBB) that, when intact, prevents antibodies and
lymphocytes from accessing the CNS. In case of disruption
or altered permeability of the BBB, aPL may be able to
cross it and react with specific autoantigens expressed by
neurons, astrocytes, and other CNS cells. Moreover, resting
lymphocytes cannot cross theBBB, but activated lymphocytes
can cross it and expand in the CSF if the autoantigen is
encountered. After this initial phase, aPL may exert a direct
pathogenetic role by direct neuronal binding. In this regard,
the ability of aPL to bind to neuronal cell surface has been
previously demonstrated in several publications. Caronti et
al. [68] showed that in experimental animal models anti-
B2GPI antibodies can bind to various cells in the CNS,
including neurons, astrocytes, and endothelial cells. More
recently, Dale et al. [69] demonstrated the presence of IgG
antibodies binding to neuronal cell surface antigens in four
paediatric patients with APS and chorea. The authors used
a neuronal cell line with dopaminergic features, suggesting
that an autoimmune mediated mechanism causing func-
tional alterations of the basal ganglia circuitry may be the
underlying pathogenetic mechanism in APS-related chorea.
Interestingly, aPL have been demonstrated to depolarize
synaptic brain rat extracts [32] and may exert a similar
function in humans. A direct binding of autoantibodies to
antigens expressed in the basal ganglia has been detected in
patients with autoimmune encephalitis characterized by var-
ious combinations of movement disorders (chorea, dystonia,
Parkinsonism, and tics) and psychiatric disturbances. The
authors detected IgG antibodies directed against dopamine
D-2 receptors in the sera of patients suffering from basal
ganglia encephalitis, a type of encephalitis that can affect both
children and adults [70].
Several autoantibodies have been detected in the past
years in autoimmune encephalitis, both in primary and
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in paraneoplastic cases [71]. In this scenario, anti-B2GPI
antibodies in APS may represent a further addition to the
already long list of antibodies directed against various CNS
antigens expressed either on the neuronal surface or at an
intracellular level.
Even if the exact antigenic specificity of aPL in the CNS
is still to be unraveled, an immunological mechanism may
explain the biological basis of chorea in APS, similarly to
other autoimmune movement disorders.
In fact, in the past years, different autoimmune basal
ganglia disorders presenting with movement disorders and
neuropsychiatric disease have been described [72]. Histor-
ically, the prototype of movement disorder caused by an
autoimmune process was represented by Sydenham’s chorea,
characterized by chorea, behavioral alterations, dysarthria,
and, less commonly, hypotonia (chorea paralytica). Syden-
ham’s chorea is thought to be caused by a molecular
mimicry mechanism following a streptococcal infection,
but, despite accumulating evidence pointing to an immune-
mediated mechanism involving the basal ganglia, no defi-
nite pathogenic autoantibodies have been detected to date.
Antibodies against lysoganglioside GM1 and tubulin [73] and
against intracellular antigens [74, 75] have been detected with
various techniques, but no definitive conclusion on their
pathogenic role in the development of clinical symptoms can
be drawn.
The hypothesis that streptococcal or other infections
could trigger basal ganglia functional alterations manifesting
with different combinations of movement disorders and
neuropsychiatric symptoms, especially tics and obsessive-
compulsive behaviour, was explored in the nineties, and
in 1998 the term PANDAS (pediatric autoimmune neu-
ropsychiatric disorders associated with streptococcus) was
coined [76]. Similarly to Sydenham’s chorea, antibodies
against lysoganglioside GM1 have been detected in some
PANDAS patients [77], while other studies failed to identify
antibodies against neuronal antigens in cultured neuron-like
cells or by means of other techniques [78–81]. Hence, several
controversies are still present in the clinical and etiological
definition of PANDAS and its overlap with other waxing and
waning tic disorders such as Tourette’s disease [72].
Within the spectrum of immune-mediated basal ganglia
diseases presenting with psychiatric symptoms and move-
ment disorders, two additional entities areworthmentioning.
The first one is NMDAR receptor encephalitis, described
for the first time as a paraneoplastic encephalitis in female
patients with ovarian teratoma [82] and later in children
and adolescents previously labeled as being affected by
encephalitis lethargica [83, 84]. In these subjects, antibodies
against an extracellular epitope located in the N-terminal
domain of the NR1 subunit of the N-methyl-D-aspartate
receptor were found to cause chorea and other hyperkinetic
movement disorders including dystonia, stereotypy, hemibal-
lismus, orofacial and limb dyskinesias, oculogyric crises, and
catatonic phenomena (waxy flexibility), as well as rigidity in
the later stages, often presenting in complex combinations
and associated with anxiety, agitation, and psychosis [72, 85].
It has been suggested that a decrease of NMDA receptors in
inhibitory GABAergic neurons and glutamatergic synapses
causes disinhibition of excitatory pathways and an increase in
extracellular glutamate, resulting in a frontostriatal syndrome
(psychosis, catatonia, mutism, rigidity, and dystonia) as
well as disinhibition of brainstem central pattern generators
causing complex elaborate movements and dyskinesias [86].
Interestingly, aPL have been suggested to interfere with
excitatory pathways in glutamatergic rat cerebellar granule
cells by a mechanism involving overactivation of the NMDA
glutamate receptor [87].
Another recently described autoimmune encephalitis is
limbic encephalitis associated with antivoltage gated potas-
sium channel (VGKC) antibodies. Also in this condition,
different movement disorders have been described, encom-
passing chorea, Parkinsonism, tremor, and myoclonus [85].
Anti-VGKC antibodies are now recognized to bind to dif-
ferent components of VGKC complexes such as leucine-
rich glioma inactivated-1 (Lgi1) [88] or contactin-associated
protein 2 (Caspr2) [89], proteins that are part of transsynaptic
complexes and neural cell adhesion molecules involved in
modulation of synaptic transmission. Characteristic facio-
brachial dystonic seizures have been described prior to the
onset of other neurological and psychiatric manifestations
of limbic encephalitis due to anti-VGKC antibodies and
should be promptly recognized and treated to prevent further
damage to the CNS [90].
All these neurological immune-mediated syndromes
share some clinical features such as a combination of
generally hyperkinetic movement disorders with different
degrees of complexity (from subtle chorea to typical upper
limb stereotypies in paraneoplastic anti-NMDAR encephali-
tis associated with ovarian teratoma) and neuropsychiatric
symptoms, subacute onset, progressing within days or weeks,
and response to steroids, intravenous immunoglobulins,
immunosuppressive agents, plasmapheresis, andmonoclonal
antibodies such as rituximab.
While ischemic manifestations of APS always imply the
initiation of either antiplatelet drugs or long-term anti-
coagulants (warfarin), no standard treatment is available
for nonvascular neurological manifestations of APS. First-
line treatment of aPL-related chorea generally includes
symptomatic antidopaminergic drugs such as haloperidol
or dopamine-depleting agents such as tetrabenazine; how-
ever, the probable flogistic/autoimmune mechanisms under-
lying these symptoms justify the use of steroids, espe-
cially in case of monotherapy failure. The European League
against Rheumatism (EULAR) recommends the use of glu-
cocorticoids or immunosuppressive agents (azathioprine,
cyclophosphamide) in severe cases of APS secondary to SLE
to control disease activity [91]. Isolated reports on the efficacy
of intravenous immunoglobulins, plasmapheresis, and ritux-
imab have been published as well, in cases with unsatisfactory
response to conventional drugs [92]. A recent pilot phase
II trial of rituximab for noncriteria APS manifestations
has been published, and its results suggest that this anti-
CD20-monoclonal antibody may be helpful in controlling
cognitive dysfunction [93]. However, randomized clinical
trials are needed to determine whether B cell depleters such
as rituximab or B cell modulators can be effective in treating
thrombotic and nonthrombotic manifestations of APS [94].
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5. Conclusion
Beyond classic thrombotic presentations such as ischemic
stroke, several polymorphic neurological manifestations of
APS have emerged over the past years, with particular interest
for those lacking a clear anatomical correlate on imaging
studies. An increasing body of evidence from experimental
APS models as well as from patients currently supports an
immune-mediated pathogenesis underlying nonthrombotic
manifestations of APS such as movement disorders and
neuropsychiatric symptoms that clearly indicate a functional
involvement of basal ganglia. Moreover, several newly recog-
nized antibodies-mediated neurological diseases have come
to light in recent years, such as anti-NMDAR and anti-VGKC
encephalitis that partially resemble APS in the type of onset,
clinical course, treatment options, and possible triggering
factors such as infections. All these complex andmultifaceted
basal ganglia autoimmune diseases represent an upcoming
challenge for clinicians, who need to promptly recognize
and effectively treat them in early stages, in order to avoid
diagnostic and therapeutic delay that may lead to a more
extensive spread of the autoimmune aggression and damage
to the CNS.
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